News

Lumoxiti, which is a CD22-directed cytotoxin, has been approved for the patients who had two or prior systemic therapies, including treatment with a purine nucleoside analog. AstraZeneca executive

Actemra can be given alone or in combination with methotrexate (MTX) in patients with SJIA. In 2011, FDA approved the intravenous (IV) formulation of Actemra for patients two

ViraTherapeutics is engaged in the development of virus-based immunotherapeutics for the treatment of cancer. The current deal is based on an option and share purchase agreement signed by

Praliciguat is an investigational, orally administered soluble guanylate cyclase (sGC) stimulator currently in Phase II clinical trials. Ironwood chief development officer and global development senior vice president Christopher

VEYVONDI should not be used in the treatment of hemophilia A. VEYVONDI is the first and only recombinant von Willebrand Factor (rVWF) treatment in the EU for von Willebrand disease (VWD)

To encourage Regeneron’s expansion in New York State, Empire State Development offered the company up to $140 million in performance-based incentives, including $70 million in Excelsior Jobs Program

The trial, dubbed IM011-011, enrolled 267 patients to assess the efficacy and safety of BMS-986165 in comparison to placebo. It delivered significant skin clearance, said the US pharma

In its advice, the SMC states that dupilumab can be used within the National Health Service (NHS) Scotland for the treatment of adults with moderate to severe atopic

Participants in the round, which was led by RiverVest Venture Partners, included new investors Qatar Investment Authority (QIA) and Redmile Group, and existing investors Alexandria Venture Investments, ARCH